iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
iSpecimen Acquires Two AI Products From Foldlab AI For $4.5M
iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
iSpecimen Supports Hospital Validation of New Chemistry Analyzer
iSpecimen To Acquire Foldlab AI Assets For $4.5M, Including AI Models, Software And Intellectual Property
iSpecimen Says On August 26, Katharyn Field To Transition From Role As Chief Executive Officer; Shahin Behroyan Appointed As Chief Executive Officer
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
iSpecimen Completes Global Cancer Research Project Of Cancer Blood Specimens; Samples Dispatched Within Three Weeks Of Getting Purchase Order
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
iSpecimen Announces 1-for-40 Reverse Stock Split
Why iSpecimen Shares Are Surging On Friday?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.